Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S A Douglas

Showing results (41-50 of 62) with videos related to

Pageof 7
Sort By:
Kidney International|March 15, 2006
Urotensin II and renal function in the ratW Song, A E S Abdel-Razik, W Lu, et al.
British Journal of Pharmacology|April 20, 2001
Differential modulation of endothelin ligand-induced contraction in isolated tracheae from endothelin B (ET(B)) receptor knockout miceD W Hay, S A Douglas, Z Ao, et al.
British Journal of Pharmacology|November 23, 2000
Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkeyS A Douglas, A C Sulpizio, V Piercy, et al.
Circulation Research|July 1, 1994
A role for endogenous endothelin-1 in neointimal formation after rat carotid artery balloon angioplasty. Protective effects of the novel nonpeptide endothelin receptor antagonist SB 209670S A Douglas, C Louden, L M Vickery-Clark, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 1, 1993
Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injuryE H Ohlstein, S A Douglas, C P Sung, et al.
Journal of Cardiovascular Pharmacology|May 22, 1998
Pharmacologic characterization of the novel, orally available endothelin-A--selective antagonist SB 247083S A Douglas, P Nambi, M Gellai, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 1, 1994
Nonpeptide endothelin receptor antagonists. II. Pharmacological characterization of SB 209670E H Ohlstein, G R Beck, S A Douglas, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 22, 2001
Pharmacology of SB-273779, a nonpeptide calcitonin gene-related peptide 1 receptor antagonistN Aiyar, R A Daines, J Disa, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 16, 1994
SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonistE H Ohlstein, P Nambi, S A Douglas, et al.
Journal of Cardiovascular Pharmacology|November 15, 2000
Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primateS A Douglas, D J Ashton, C F Sauermelch, et al.
Pageof 7

Showing results (41-50 of 62) with videos related to

Sort By:
Pageof 7
Kidney International|March 15, 2006
Urotensin II and renal function in the ratW Song, A E S Abdel-Razik, W Lu, et al.
British Journal of Pharmacology|April 20, 2001
Differential modulation of endothelin ligand-induced contraction in isolated tracheae from endothelin B (ET(B)) receptor knockout miceD W Hay, S A Douglas, Z Ao, et al.
British Journal of Pharmacology|November 23, 2000
Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkeyS A Douglas, A C Sulpizio, V Piercy, et al.
Circulation Research|July 1, 1994
A role for endogenous endothelin-1 in neointimal formation after rat carotid artery balloon angioplasty. Protective effects of the novel nonpeptide endothelin receptor antagonist SB 209670S A Douglas, C Louden, L M Vickery-Clark, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 1, 1993
Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injuryE H Ohlstein, S A Douglas, C P Sung, et al.
Journal of Cardiovascular Pharmacology|May 22, 1998
Pharmacologic characterization of the novel, orally available endothelin-A--selective antagonist SB 247083S A Douglas, P Nambi, M Gellai, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 1, 1994
Nonpeptide endothelin receptor antagonists. II. Pharmacological characterization of SB 209670E H Ohlstein, G R Beck, S A Douglas, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 22, 2001
Pharmacology of SB-273779, a nonpeptide calcitonin gene-related peptide 1 receptor antagonistN Aiyar, R A Daines, J Disa, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 16, 1994
SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonistE H Ohlstein, P Nambi, S A Douglas, et al.
Journal of Cardiovascular Pharmacology|November 15, 2000
Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primateS A Douglas, D J Ashton, C F Sauermelch, et al.
Pageof 7